SGLT-2 inhibition may restore tubuloglomerular feedback and reduce intraglomerular pressure through non-glycaemic mechanisms in people with diabetes (including those already on RAS blockade) [31, 33, 44] and has acute effects on GFR in people without diabetes [54–56]. The gene discussed is SLC5A2; the disease is diabetes mellitus.